El Profesor Ian Judson, del Royal Marsden Hospital de Londres, Reino Unido, indicó que los estudios clínicos realizados en más de 386 pacientes demuestran que Yondelis, a la dosis de 1,5 mg/m2 cada 3 semanas, tiene un perfil de seguridad manejable. “Es de destacar el hecho de que este agente no se asocia a efectos secundarios acumulativos, siendo éstos reversibles y transitorios. Esto permite continuar el tratamiento en aquellos pacientes que responden, sin límite en el número de ciclos administrados” añadió Judson. A fecha de hoy más de 1.800 pacientes han sido tratados con Yondelis.
07 diciembre 2007
Prof Ian Judson, Clinical medical oncologist, on the latest new treatment Yondelis® for metastatic or advanced soft tissue sarcoma . ( Video ) .
El Profesor Ian Judson, del Royal Marsden Hospital de Londres, Reino Unido, indicó que los estudios clínicos realizados en más de 386 pacientes demuestran que Yondelis, a la dosis de 1,5 mg/m2 cada 3 semanas, tiene un perfil de seguridad manejable. “Es de destacar el hecho de que este agente no se asocia a efectos secundarios acumulativos, siendo éstos reversibles y transitorios. Esto permite continuar el tratamiento en aquellos pacientes que responden, sin límite en el número de ciclos administrados” añadió Judson. A fecha de hoy más de 1.800 pacientes han sido tratados con Yondelis.
The Lancet Oncology - Vol. 8, Issue 12, December 2007, Page 1061 . Trabectedin too toxic in ovarian cancer ? .
LANCET ONCOLOGY
Trabectedin too toxic in ovarian cancer
Sally Simpson
Available online 3 December 2007.
Trabectedin shows modest activity but substantial toxic effects in the treatment of ovarian cancer (Br J Cancer, published online Nov 13, 2007; DOI:10.1038/sj.bjc.6604088).
Carolyn Krasner (Massachusetts General Hospital, Boston, MA, USA) and colleagues did a phase II study on 147 patients with ovarian cancer, who had all previously had platinum-containing chemotherapy. 66 patients sensitive to platinum chemotherapy and 81 patients resistant to platinum chemotherapy were given trabectedin via a central venous catheter once weekly for three weeks on a 28 day cycle.
141 patients were assessable by use of Response Evaluation Criteria in Solid Tumors (RECIST) after treatment. Four patients had a complete response, but all four were patients who were sensitive to platinum-contain chemotherapy. In the rest of the platinum-sensitive group, 14 patients had a partial response, 22 had stable disease, and 22 had progressive disease. In the platinum resistant group, five patients had a partial response, 36 had stable disease, and 38 had progressive disease.
146 of 147 patients reported toxic effects, the most common of which were granulocytopenia, nausea, vomiting, and fatigue. Five patients died during treatment or within 30 days of the last dose.
Krasner says “trabectedin is an active agent in the treatment of ovarian cancer and will add to the armementarium used to treat this deadly disease”.
Maurie Markman (MD Anderson Cancer Center, Houston, TX, USA) is concerned by the toxic effects noted in the study. He adds, “this phase II trial has revealed trabectedin to be an active agent in ovarian cancer. However, defining a possible role for this drug will require future investigative efforts, especially considering the fact several other agents have demonstrated similar levels of activity in this clinical setting”.
Trabectedin too toxic in ovarian cancer
Sally Simpson
Available online 3 December 2007.
Trabectedin shows modest activity but substantial toxic effects in the treatment of ovarian cancer (Br J Cancer, published online Nov 13, 2007; DOI:10.1038/sj.bjc.6604088).
Carolyn Krasner (Massachusetts General Hospital, Boston, MA, USA) and colleagues did a phase II study on 147 patients with ovarian cancer, who had all previously had platinum-containing chemotherapy. 66 patients sensitive to platinum chemotherapy and 81 patients resistant to platinum chemotherapy were given trabectedin via a central venous catheter once weekly for three weeks on a 28 day cycle.
141 patients were assessable by use of Response Evaluation Criteria in Solid Tumors (RECIST) after treatment. Four patients had a complete response, but all four were patients who were sensitive to platinum-contain chemotherapy. In the rest of the platinum-sensitive group, 14 patients had a partial response, 22 had stable disease, and 22 had progressive disease. In the platinum resistant group, five patients had a partial response, 36 had stable disease, and 38 had progressive disease.
146 of 147 patients reported toxic effects, the most common of which were granulocytopenia, nausea, vomiting, and fatigue. Five patients died during treatment or within 30 days of the last dose.
Krasner says “trabectedin is an active agent in the treatment of ovarian cancer and will add to the armementarium used to treat this deadly disease”.
Maurie Markman (MD Anderson Cancer Center, Houston, TX, USA) is concerned by the toxic effects noted in the study. He adds, “this phase II trial has revealed trabectedin to be an active agent in ovarian cancer. However, defining a possible role for this drug will require future investigative efforts, especially considering the fact several other agents have demonstrated similar levels of activity in this clinical setting”.
Patente UA . USE OF YONDELIS IN COMBINATION THERAPY FOR SARCOMA TREATMENT .
Publication number: UA79926
Publication date: 2007-08-10
Inventor: TAKAHASI NAOTO (US); WEITMEN STEVE (US); DINKALCHEE MAURITSIO (IT); FERCLOT HLINN THOMAS (US); JAVATSEE RAPHAELLA (IT); HESHER ANDREAS (GB)
Applicant: PHARMA MAR SA (ES)
Classification:
- international: A61K31/282; A61K31/351; A61K31/495; A61P35/00; A61K31/28; A61K; A61K31/351; A61K31/495; A61P35/00;
- European:
Application number: UA20030065206 20011106
Priority number(s): US20000246233P 20001106; WO2001GB04902 20011106
Abstract of UA79926
ET-743 Ecteinascidin is used in the preparation of a medicament for an effective sarcoma treatment by combination therapy employing ET-743 with another drug - anthracyclin or antitumor agent based on platinum.
Publication date: 2007-08-10
Inventor: TAKAHASI NAOTO (US); WEITMEN STEVE (US); DINKALCHEE MAURITSIO (IT); FERCLOT HLINN THOMAS (US); JAVATSEE RAPHAELLA (IT); HESHER ANDREAS (GB)
Applicant: PHARMA MAR SA (ES)
Classification:
- international: A61K31/282; A61K31/351; A61K31/495; A61P35/00; A61K31/28; A61K; A61K31/351; A61K31/495; A61P35/00;
- European:
Application number: UA20030065206 20011106
Priority number(s): US20000246233P 20001106; WO2001GB04902 20011106
Abstract of UA79926
ET-743 Ecteinascidin is used in the preparation of a medicament for an effective sarcoma treatment by combination therapy employing ET-743 with another drug - anthracyclin or antitumor agent based on platinum.